JANXJanux Therapeutics, Inc.

$852M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-55.3% YoY

Gross Profit

-$14M-1311.9% margin

Operating Income

-$21M-1962.9% margin

Net Income

-$18M-1656.4% margin

EPS (Diluted)

$-0.42

QoQ Revenue Growth

-48.4%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$16M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$342M

Total Liabilities

$42M

Stockholders' Equity

$299M

Cash & Equivalents

$34M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$2M	-55.3%
Gross Profit	-$14M	-$12M	-18.3%
Operating Income	-$21M	-$17M	-20.2%
Net Income	-$18M	-$17M	-3.7%

JANX Q2 2023 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena